Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 8/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.42 |
| ▸ | MTOR | P42345 | 4/20 | 0.41 |
| ▸ | ATR | Q13535 | 11/20 | 0.39 |
| ▸ | ATRIP | Q8WXE1 | 10/20 | 0.39 |
| ▸ | PDCD1 | Q15116 | 9/20 | 0.37 |
| ▸ | CD274 | Q9NZQ7 | 9/20 | 0.37 |
| ▸ | CHEK1 | O14757 | 8/20 | 0.37 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.36 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.36 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4202437 | 0.95 | PIK3CA (0.43) | PIK3CAPIK3CDMTORATRATRIP | |
| SCHEMBL1706234 | 0.84 | PIK3CA (0.48) | PIK3CAPIK3CDMTORATRATRIP | |
| SCHEMBL738597 | 0.84 | PIK3CA (0.48) | PIK3CAPIK3CDMTORATRATRIP | |
| SCHEMBL739891 | 0.82 | PIK3CA (0.42) | PIK3CAPIK3CDATRATRIPPDCD1 | |
| SCHEMBL3596174 | 0.82 | PIK3CA (0.50) | PIK3CAPIK3CDMTORATRATRIP | |
| SCHEMBL4194712 | 0.82 | ATR (0.44) | PIK3CAMTORATRATRIP | |
| SCHEMBL2493212 | 0.81 | PIK3CA (0.51) | PIK3CAPIK3CDMTORATRATRIP | |
| SCHEMBL2493217 | 0.81 | PIK3CA (0.51) | PIK3CAPIK3CDMTORATRATRIP | |
| SCHEMBL3596412 | 0.81 | PIK3CA (0.51) | PIK3CAPIK3CDMTORATRATRIP | |
| SCHEMBL4201704 | 0.80 | ATR (0.41) | PIK3CAMTORATRATRIP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2057140-B1 | MORPHOLINO PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2012-08-08 | — | — | EP | disclosed |
| EP-2176238-B1 | MORPHOLINO PYRIMIDINE DERIVATIVES USED IN DISEASES LINKED TO MTOR KINASE AND/OR PI3K | ASTRAZENECA AB (SE) | 2012-04-18 | — | — | EP | disclosed |
| US-8138183-B2 | Morpholino pyrimidine derivatives used in diseases linked to mTOR kinase and/or PI3K | ASTRAZENECA AB (SE) | 2012-03-20 | — | — | US | disclosed |
| US-8138183-B2 | Morpholino pyrimidine derivatives used in diseases linked to mTOR kinase and/or PI3K | ASTRAZENECA AB (SE) | 2012-03-20 | — | — | US | disclosed |
| US-20100249131-A1 | MORPHOLINO PYRIMIDINE DERIVATIVES USED IN DISEASES LINKED TO MTOR KINASE AND/OR PI3K | ASTRAZENECA AB (SE) | 2010-09-30 | — | — | US | disclosed |
| US-20100249131-A1 | MORPHOLINO PYRIMIDINE DERIVATIVES USED IN DISEASES LINKED TO MTOR KINASE AND/OR PI3K | ASTRAZENECA AB (SE) | 2010-09-30 | — | — | US | disclosed |
| US-7750003-B2 | Compounds-943 | ASTRAZENECA AB (SE) | 2010-07-06 | — | — | US | disclosed |
| EP-2074118-A2 | TRISUBSTITUTED PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | AstraZeneca AB (SE) | 2009-07-01 | — | — | EP | disclosed |
| US-20090018134-A1 | Compounds - 945 | ASTRAZENECA AB (SE) | 2009-01-15 | — | — | US | disclosed |
| US-20090018134-A1 | Compounds - 945 | ASTRAZENECA AB (SE) | 2009-01-15 | — | — | US | disclosed |
| WO-2009007748-A2 | TRISUBSTITUTED PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | ASTRAZENECA AB (SE) | 2009-01-15 | — | — | WO | disclosed |
| US-20080171743-A1 | Transcutaneous immunostimulation | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018134-A1 | Compounds - 945 | MTOR, PIK3CA, PIK3R5 | PIK3CA 2/4885PIK3CD 4/4885MTOR 1/4885 |
| US-20080171743-A1 | Transcutaneous immunostimulation | NFATC1, TLR9, MTOR | PIK3CA 20/4885PIK3CD 19/4885MTOR 3/4885 |
| US-20100249131-A1 | MORPHOLINO PYRIMIDINE DERIVATIVES USED IN DISEASES LINKED TO MTOR KINASE AND/OR PI3K | PIK3CA, MTOR, PIK3CD | PIK3CA 1/4885PIK3CD 3/4885MTOR 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.